Mandate

Vinge advises on equity line and rights issue guarantee to Karo Bio

October 27, 2010

Azimuth Opportunity, Inc and Karo Bio AB (publ) (NASDAQ OMX Stockholm) have entered an agreement regarding a so-called Equity Credit Facility, whereby Azimuth has undertaken to subscribe for new shares in Karo Bio on Karo Bio’s request and as set out in the terms of the facility, of up to USD 35 million. In addition, Azimuth guarantees part of Karo Bio’s rights issue of approx. SEK 300 million. The Facility and the rights issue are subject to approval by the general meeting of Karo Bio.

Vinge advises Azimuth. Vinge’s team is headed by capital markets partner Erik Sjöman.

Related

Vinge advises Summit Partners on its $1 billion-plus investment in Keyfactor

Vinge has, together with Kirkland & Ellis, advised Summit Partners in connection with a strategic growth investment in Keyfactor, a leader in trust infrastructure. The investment will help accelerate the company's global scale and growth initiatives, enabling product innovation, geographic expansion, team building and strategic acquisitions.
July 20, 2026

Vinge has advised VAROPreem in connection with its acquisition of Sunpine

Vinge has advised VAROPreem in connection with its acquisition of Sunpine from Sveaskog, Södra Skogsägarna and Lawter.
July 10, 2026

Vinge advises Consolid Equity in connection with the establishment of Petra Group

Vinge has advised Consolid Equity Investment AB ("Consolid Equity") on the acquisition of Ström & Gulliksson, one of the leading patent agencies in the Nordics. The acquisition forms part of the establishment of Petra Group, a European platform aimed at consolidating patent agencies across Europe to combine expertise and resources primarily within patents and trademarks. Consolid acts as a strategic partner in the new group.
July 08, 2026